Akums Drugs and Pharmaceuticals IPO GMP Today in the Grey Market is Not Available at The Moment. Investors are Advised to Closely Monitor Market Trends and consult Reliable Sources for the Most up-to-date Information. It is important to Exercise Caution and Conduct Thorough Research Before Making Any Investment Decisions.
About Akums Drugs and Pharmaceuticals IPO-
How Much GMP Price Akums Drugs and Pharmaceuticals IPO today?, live Grey Market Premium Kostak Rates today live Akums Drugs and Pharmaceuticals IPO Now. Subject to sauda Rate today, Akums Drugs and Pharmaceuticals IPO as of today Subject to sauda rates kostak. Akums Drugs and Pharmaceuticals IPO is to open on 30 July 2024 & Close on 1 August 2024. Akums Drugs and Pharmaceuticals is a Mainline IPO to Raise 27,345,162 shares (Appprox ₹1,856.74 Cr) Via IPO. The Akums Drugs and Pharmaceuticals IPO Price Band is Fixed At ₹679 Per Every Share With a IPO Lot Size of 22 Shares.
About Akums Drugs and Pharmaceuticals Data Like –
- Mr. Sandeep Jain is the CEO of Akums Drugs and Pharmaceuticals and Akums Drugs and Pharmaceuticals was founded in the year 2004 and has just completed 19 years in operation.
- Akums Drugs and Pharmaceuticals of our other services include formulation research and development (“R&D”), preparation and filing of regulatory dossiers in the Indian and global markets, and other testing services. In addition to our core CDMO business. we are also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (“APIs”) .
- We produce an extensive range of dosage forms including tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies, among others. we have manufactured 4,025 commercialised formulations across over 60 dosage forms.
Akums Drugs and Pharmaceuticals IPO GMP With Per Lot Profit
| DATE | IPO GMP PRICE | EST LISTING PRICE |
|---|---|---|
| 06 Aug | ₹44 | ₹723 |
| 05 Aug | ₹44 | ₹723 |
| 04 Aug | ₹85 | ₹764 |
| 03 Aug | ₹100 | ₹779 |
| 02 Aug | ₹125 | ₹804 |
| 01 Aug | ₹141 | ₹820 |
| 31 July | ₹171 | ₹850 |
| 30 July | ₹191 | ₹870 |
| 29 July | ₹212 | ₹891 |
| 28 July | ₹181 | ₹860 |
| 27 July | ₹171 | ₹850 |
| 26 July | ₹166 | ₹845 |
| 25 July | ₹167 | ₹846 |
Also Read : Akums Drugs and Pharmaceuticals IPO Details Today, GMP Price, Date, Review
Latest IPO GMP
We Update live GMP status of all upcoming IPOs every day until the IPO gets listed on the stock exchange. You can easily see the GMP price of all IPOs on our IPO GMP dashboard. We update IPO GMP performance regularly on Moneymintidea.com. You can easily get a rough idea of the GMP of all IPOs and what the listing price of the IPO is going to be.
IPO Grey Market Premium (GMP)
Before investing money in any IPO, one should pay more attention to the fact that the IPO GMP price is very volatile, if you are thinking of investing in Akums Drugs and Pharmaceuticals IPO by looking at the GMP price, then your decision may prove to be quite risky. Before investing in a new IPO, you should have good knowledge about the business of the company. It should be your decision whether to invest in Akums Drugs and Pharmaceuticals IPO or not and not by looking at the GMP price of the IPO.
Grey Market Premium (GMP) is the price at which an IPO is traded in an informal/unregulated manner before getting listed on the stock exchange. GMP price in the gray market reflects the price at which a company’s IPO is listed. Going to do. A good GMP premium/price gives you an indication of how much profit the IPO will make upon listing. Rather, if the GMP premium of an IPO is negative, then one should avoid investing money in that IPO.
Disclaimer:- The article here should not be construed as an offer to you to buy or sell based on any IPO / Gray Market Premium (GMP) or as advice in any way. The article here is written for informational and educational informational purposes only. This article should not be relied upon for investing in IPOs. Readers should consult a qualified financial advisor before making investment decisions.
Any reader making any investment decision based on the information published here does so entirely at his own risk. Investors should be aware that any investment in the equity market is subject to unpredictable market-related risks. The author does not intend to invest in this offering.
